Insights into the molecular mechanisms of plaque rupture and thrombosis

Biochemistry of Atherosclerosis

Volumn , Issue , 2006, Pages 455-472

  Shah, P K ^a   Sharifi, Behrooz ^a  

^a BURNS AND ALLEN RESEARCH INSTITUTE   (United States)

Author keywords

Atherosclerosis; inflammation; plaque erosion; plaque rupture; thrombosis

Indexed keywords

EID: 84900631692     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/0-387-36279-3_21     Document Type: Chapter

References (155)

1. Murray CJ, Lopez AD: Global mortality, disability and contribution of risk factors: Global Bureau of Disease Study. Lancet 349: 1436-1442, 1997.
2. Falk E, Shah PK, Fuster V: Coronary plaque disruption. Circulation 92: 657-671, 1995.
3. Virmani R, Burke AP, Farb A: Plaque rupture and plaque erosion. Thromb Haemat 82 (Suppl 1): 1-3, 1999.
4. Shah PK: Pathophysiology of coronary thrombosis: role of plaque rupture and plaque erosion. Prog Cardiovasc Dis 44: 357-368, 2002.
5. Libby P: Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 104: 365-372, 2001.
6. DeWood MA, Spores J, Notske R, et al: Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 303: 897-902, 1980.
7. DeWood MA, Spores J, Hensley GR, et al: Coronary arteriographic findings in acute transmural myocardial infarction. Circulation 68: I39-I49, 1983.
8. DeWood MA, Stifter WF, Simpson CS, et al: Coronary arteriographic findings soon after non-Q-wave myocardial infarction. N Engl J Med 315: 417-423, 1986.
9. Levin DC, Fallon JT: Significance of the angiographic morphology of localized coronary stenoses: histopathologic correlations. Circulation 66: 316-320, 1982.
10. Sherman CT, Litvack F, Grundfest W, et al: Coronary angioscopy in patients with unstable angina pectoris. N Engl J Med 315: 913-919, 1986.
11. Kruskal JB, Commerford PJ, Franks JJ, Kirsch RE: Fibrin and fibrinogen-related antigens in patients with stable and unstable coronary artery disease. N Engl J Med 317: 1361-1365, 1987.
12. Folts JD: Platelet aggregation in stenosed coronary or cerebral arteries: a mechanism for sudden death? Wis Med J 79: 24-26, 1980.
13. Davies MJ, Thomas A: Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med 310: 1137-1140, 1984.
14. Falk E: Plaque rupture with severe pre-existing stenosis precipitating coronary thrombosis. Characteristics of coronary atherosclerotic plaques underlying fatal occlusive thrombi. Br Heart J 50: 127-134, 1983.
15. Ambrose JA, Winters SL, Stern A, et al: Angiographic morphology and the pathogenesis of unstable angina pectoris. J Am Coll Cardiol 5: 609-616, 1985.
16. Ambrose JA, Winters SL, Arora RR, et al: Coronary angiographic morphology in myocardial infarction: a link between the pathogenesis of unstable angina and myocardial infarction. J Am Coll Cardiol 6: 1233-1238, 1985.
17. Gorlin R, Fuster V, Ambrose JA: Anatomic-physiologic links between acute coronary syndromes. Circulation 74: 6-9, 1986.
18. Friedman M: Pathogenesis of coronary thrombosis, intramural and intraluminal hemorrhage. Adv Cardiol 4: 20-46, 1970.
19. Friedman M: The pathogenesis of coronary plaques, thromboses, and hemorrhages: an evaluative review. Circulation 52: III34-III40, 1975.
20. Constantinides P: Atherosclerosis-a general survey and synthesis. Surv Synth Pathol Res 3: 477-498, 1984.
21. Ambrose JA, Hjemdahl-Monsen C, Borrico S, et al: Quantitative and qualitative effects of intracoronary streptokinase in unstable angina and non-Q wave infarction. J Am Coll Cardiol 9: 1156-1165, 1987.
22. Ambrose JA, Winters SL, Arora RR, et al: Angiographic evolution of coronary artery morphology in unstable angina. J Am Coll Cardiol 7: 472-478, 1986.
23. Ambrose JA, Monsen C: Significance of intraluminal filling defects in unstable angina. Am J Cardiol 57: 1003-1004, 1986.
24. Little WC, Constantinescu M, Applegate RJ, et al: Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation 78: 1157-1166, 1988.
25. Hackett D, Davies G, Maseri A: Pre-existing coronary stenoses in patients with first myocardial infarction are not necessarily severe. Eur Heart J 9: 1317-1323, 1988.
26. Giroud D, Li JM, Urban P, Meier B, Rutishauer W: Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Am J Cardiol 69: 729-732, 1992.
27. Brown G, Albers JJ, Fisher LD, et al: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 323: 1289-1298, 1990.
28. Naqvi TZ, Hachamovitch R, Berman D, Buchbinder N, Kiat H, Shah PK: Does the presence and site of myocardial ischemia on perfusion scintigraphy predict the occurrence and site of future myocardial infarction in patients with stable coronary artery disease? Am J Cardiol 79: 1521-1524, 1997.
29. Shah PK: Plaque size, vessel size and plaque vulnerability: bigger may not be better. J Am Coll Cardiol 32: 663-664, 1998.
30. Schoenhagen P, Ziada KM, Kapadia SR, Crowe TD, Nissen SE, Tuzcu EM: Extent and direction of arterial remodeling in stable versus unstable coronary syndromes: an intravascular ultrasound study. Circulation 101: 598-603, 2000.
31. von Birgelen C, Klinkhart W, Mintz GS, et al: Plaque distribution and vascular remodeling of ruptured and nonruptured coronary plaques in the same vessel: an intravascular ultrasound study in vivo. J Am Coll Cardiol 37: 1864-1870, 2001.
32. Takano M, Mizuno K, Okamatsu K, Yokoyama S, Ohba T, Sakai S: Mechanical and structural characteristics of vulnerable plaques: analysis by coronary angioscopy and intravascular ultrasound. J Am Coll Cardiol 38: 99-104, 2001.
33. Loree HM, Kamm RD, Stringfellow RG, Lee RT: Effects of fibrous cap thickness on peak circumferential stress in model atherosclerotic vessels. Circ Res 71: 850-858, 1992.
34. Varnava AM, Mills PG, Davies MJ: Relationship between coronary artery remodeling and plaque vulnerability. Circulation 105: 939-943, 2002.
35. Guyton JR, Klemp KF: Development of the lipid-rich core in human atherosclerosis. Arterioscler Thromb Vasc Biol 16: 4-11, 1996.
36. Richardson PD, Davies MJ, Born GV: Influence of plaque configuration and stress distribution on fissuring of coronary atherosclerotic plaques. Lancet 2: 941-944, 1989.
37. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J: Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 69: 377-381, 1993.
38. Felton CV, Crook D, Davies MJ, Oliver MF: Relation of plaque lipid composition and morphology to the stability of human aortic plaques. Arterioscler Thromb Vasc Biol 17: 1337-1345, 1997.
39. Burleigh MC, Briggs AD, Lendon CL, Davies MJ, Born GV, Richardson PD: Collagen types I and III, collagen content, GAGs and mechanical strength of human atherosclerotic plaque caps: span-wise variations. Atherosclerosis 96: 71-81, 1992.
40. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT: Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 90: 775-778, 1994.
41. Moreno PR, Bernardi VH, Lopez-Cuellar J, et al: Macrophages, smooth muscle cells, and tissue factor in unstable angina. Implications for cell-mediated thrombo-genicity in acute coronary syndromes. Circulation 94: 3090-3097, 1996.
42. Lendon CL, Davies MJ, Born GV, Richardson PD: Atherosclerotic plaque caps are locally weakened when macrophages density is increased. Atherosclerosis 87: 87-90, 1991.
43. Depre C, Havaux X, Wijns W. Neovascularization in human coronary atherosclerotic lesions. Cathet Cardiovasc Diagn 39: 215-220, 1996.
44. Tenaglia AN, Peters KG, Sketch MH Jr, Annex BH: Neovascularization in atherectomy specimens from patients with unstable angina: implications for pathogenesis of unstable angina. Am Heart J 135: 10-14, 1998.
45. Feng B, Yao PM, Li Y, Devlin CM, Zhang D, Harding HP, Sweeney M, Rong JX, Kuriakes G, Fisher EA, Marks AR, Ron D, Tabas I: The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages. Nat Cell Biol 5: 781-792, 2003.
46. Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, Farb A, Guerrero LJ, Hayase M, Kutys R, Narula J, Finn AV, Virmani R: Intraplaque hemorrhage and progression of atheroma. N Engl J Med 349: 2316-2325, 2003.
47. Cheng GC, Loree HM, Kamm RD, Fishbein MC, Lee RT: Distribution of circumferential stress in ruptured and stable atherosclerotic lesions. A structural analysis with histopathological correlation. Circulation 87: 1179-1187, 1993.
48. Loree HM, Tobias BJ, Gibson LJ, Kamm RD, Small DM, Lee RT: Mechanical properties of model atherosclerotic lesion lipid pools. Arterioscler Thromb 14: 230-234, 1994.
49. Huang H, Virmani R, Younis H, Burke AP, Kamm RD, Lee RT: The impact of calcification on the biomechanical stability of atherosclerotic plaques. Circulation 103: 1051-1056, 2001.
50. Faber BC, Cleutjens KB, Niessen RL, et al: Identification of genes potentially involved in rupture of human atherosclerotic plaques. Circ Res 89: 547-554, 2001.
51. Essler M, Retzer M, Bauer M, Zangl KJ, Tigyi G, Siess W: Stimulation of platelets and endothelial cells by mildly oxidized LDL proceeds through activation of lysophosphatidic acid receptors and the Rho/Rho-kinase pathway. Inhibition by lovastatin. Ann N Y Acad Sci 905: 282-286, 2000.
52. Toschi V, Gallo R, Lettino M, et al: Tissue factor modulates the thrombogenic-ity of human atherosclerotic plaques. Circulation 95: 594-599, 1997.
53. Mallat Z, Hugel B, Ohan J, Leseche G, Freyssinet JM, Tedgui A: Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. Circulation 99: 348-353, 1999.
54. Badimon JJ, Lettino M, Toschi V, et al: Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 99: 1780-1787, 1999.
55. Fernandez-Ortiz A, Badimon JJ, Falk E, et al: Characterization of the relative thrombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture. J Am Coll Cardiol 23: 1562-1569, 1994.
56. van der Wal AC, Becker AE, van der Loos CM, Das PK: Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 89: 36-44, 1994.
57. Kovanen PT: The mast cell-a potential link between inflammation and cellular cholesterol deposition in atherogenesis. Eur Heart J 14 (Suppl K): 105-117, 1993.
58. Kovanen PT, Kaartinen M, Paavonen T: Infiltrates of activated mast cells at the site of coronary atheromatous erosion or rupture in myocardial infarction. Circulation 92: 1084-1088, 1995.
59. Kaartinen M, van der Wal AC, van der Loos CM, et al: Mast cell infiltration in acute coronary syndromes: implications for plaque rupture. J Am Coll Cardiol 32: 606-612, 1998.
60. Laine P, Kaartinen M, Penttila A, Panula P, Paavonen T, Kovanen PT: Association between myocardial infarction and the mast cells in the adventitia of the infarct-related coronary artery. Circulation 99: 361-369, 1999.
61. Libby P: Inflammation in atherosclerosis. Nature 420: 868-874, 2002.
62. Barger AC, Beeuwkes R III, Lainey LL, Silverman KJ. Hypothesis: vasa vaso-rum and neovascularization of human coronary arteries. A possible role in the pathophysiology of atherosclerosis. N Engl J Med 310: 175-177, 1984.
63. Kamat BR, Galli SJ, Barger AC, Lainey LL, Silverman KJ: Neovascularization and coronary atherosclerotic plaque: cinematographic localization and quantitative histologic analysis. Hum Pathol 18: 1036-1042, 1987.
64. Barger AC, Beeuwkes R III: Rupture of coronary vasa vasorum as a trigger of acute myocardial infarction. Am J Cardiol 66: 41G-43G, 1990.
65. Heistad DD, Armstrong ML: Blood flow through vasa vasorum of coronary arteries in atherosclerotic monkeys. Arteriosclerosis 6: 326-331, 1986.
66. Williams JK, Heistad DD: The vasa vasorum of the arteries. J Mal Vasc 21: 266-269, 1996.
67. Kwon HM, Sangiorgi G, Ritman EL, et al: Enhanced coronary vasa vasorum neovascularization in experimental hypercholesterolemia. J Clin Invest 101: 1551-1556, 1998.
68. Gojova A, Brun V, Bruno E, Cottrez F, Gourdy P, Ardouin P, Tedgui A, Mallat Z, Groux H: Specific abrogation of transforming growth factor beta signaling in T cells alters atherosclerolic lesion size and composition in mice. Blood 102: 4052-4058, 2003.
69. Robertson AL, Rudling M, Zhore X, Gorelik L, Flavell RA, Hansson GK: Disruption of TGF-beta signaling in T-cells accelerates atherosclerosis. J Clin Invest 112: 1342-1350, 2003.
70. Tedgui A, Mallat Z: Anti-inflammatory mechanisms in the vascular wall. Circ Res 88: 877-887, 2001.
71. Xu XH, Shah PK, Faure E, Equils O, Thomas L, Fishbein MC, Luthringer D, Xu XP, Rajavashisth TB, Yano J, Kaul S, Arditi M: Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregu-lated by oxidized LDL. Circulation. 104(25): 3103-3108, 2001.
72. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, Arditi M: Lack of toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci USA 101(29): 10679-10684, 2004.
73. Henney AM, Wakeley PR, Davies MJ, et al: Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci USA 88: 8154-8158, 1991.
74. Galis ZS, Sukhova GK, Lark MW, Libby P: Increased expression of matrix met-alloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 94: 2493-2503, 1994.
75. Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM: Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation 91: 2125-2131, 1995.
76. Nikkari ST, O'Brien KD, Ferguson M, et al: Interstitial collagenase [MMP-1] expression in human carotid atherosclerosis. Circulation 92: 1393-1398, 1995.
77. Li Z, Li L, Zielke HR, et al: Increased expression of 72-kD type IV collagenase [MMP-2] in human aortic atherosclerotic lesions. Am J Pathol 148: 121-128, 1996.
78. Galis ZS, Sukhova GK, Libby P: Microscopic localization of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue. FASEB J 9: 974-980, 1995.
79. Xu XP, Meisel SR, Ong JM, et al: Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation 99: 993-998, 1999.
80. Rajavashisth TB, Xu XP, Jovinge S, et al: Membrane type 1 matrix metallopro-teinase expression in human atherosclerotic plaques: evidence for activation by proinflammatory mediators. Circulation 99: 3103-3109, 1999.
81. Rajavashisth TB, Liao JK, Galis ZS, et al: Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. J Biol Chem 274: 11924-11929, 1999.
82. Herman MP, Sukhova GK, Libby P, et al: Expression of neutrophil collagenase [matrix metalloproteinase-8] in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation 104: 1899-1904, 2001.
83. Shah PK, Falk E, Badimon JJ, et al: Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation 92: 1565-1569, 1995.
84. Shah PK: Role of inflammation and metalloproteinases in plaque disruption and thrombosis. Vasc Med 3: 199-206, 1998.
85. Sukhova GK, Schonbeck U, Rabkin E, et al: Evidence for increased collagenol-ysis by interstitial collagenases-1 and-3 in vulnerable human atheromatous plaques. Circulation 99: 2503-2509, 1999.
86. Lee RT, Schoen FJ, Loree HM, Lark MW, Libby P: Circumferential stress and matrix metalloproteinase 1 in human coronary atherosclerosis. Implications for plaque rupture. Arterioscler Thromb Vasc Biol 16: 1070-1073, 1996.
87. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Libby P: Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann N Y Acad Sci 748: 501-507, 1995.
88. Galis ZS, Sukhova GK, Kranzhofer R, Clark S, Libby P: Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading pro-teinases. Proc Natl Acad Sci USA 92: 402-406, 1995.
89. Kol A, Sukhova GK, Lichtman AH, Libby P. Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression. Circulation 98: 300-307, 1998.
90. Mach F, Schonbeck U, Fabunmi RP, et al: T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L-dependent mechanism: implications for tubule formation. Am J Pathol 154: 229-238, 1999.
91. Schonbeck U, Mach F, Sukhova GK, et al: Regulation of matrix metallopro-teinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? Circ Res 81: 448-454, 1997.
92. Wallner K, Li C, Shah PK, et al: Tenascin-C is expressed in macrophage-rich human coronary atherosclerotic plaque. Circulation 99: 1284-1289, 1999.
93. Sukhova GK, Shi GP, Simon DI, Chapman HA, Libby P: Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest 102: 576-583, 1998.
94. Shi GP, Sukhova GK, Grubb A, et al: Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest 104: 1191-1197, 1999.
95. Bennett MR, Evan GI, Schwartz SM: Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J Clin Invest 95: 2266-2274, 1995.
96. Bjorkerud S, Bjorkerud B: Apoptosis is abundant in human atherosclerotic lesions, especially in inflammatory cells [macrophages and T cells], and may contribute to the accumulation of gruel and plaque instability. Am J Pathol 149: 367-380, 1996.
97. Kockx MM, Knaapen MW: The role of apoptosis in vascular disease. J Pathol 190: 267-280, 2000.
98. Ihling C, Haendeler J, Menzel G, et al: Co-expression of p53 and MDM2 in human atherosclerosis: implications for the regulation of cellularity of atherosclerotic lesions. J Pathol 185: 303-312, 1998.
99. Crisby M, Kallin B, Thyberg J, et al: Cell death in human atherosclerotic plaques involves both oncosis and apoptosis. Atherosclerosis 130: 17-27, 1997.
100. Bennett MR: Apoptosis of vascular smooth muscle cells in vascular remodelling and atherosclerotic plaque rupture. Cardiovasc Res 41: 361-368, 1999.
101. Galle J, Heermeier K, Wanner C: Atherogenic lipoproteins, oxidative stress, and cell death. Kidney Int Suppl 71: S62-S65, 1999.
102. Vieira O, Escargueil-Blanc I, Jurgens G, et al: Oxidized LDLs alter the activity of the ubiquitin-proteasome pathway: potential role in oxidized LDL-induced apoptosis. FASEB J 14: 532-542, 2000.
103. Rossig L, Dimmeler S, Zeiher AM: Apoptosis in the vascular wall and atherosclerosis. Basic Res Cardiol 96: 11-22, 2001.
104. Geng YJ, Wu Q, Muszynski M, Hansson GK, Libby P: Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alpha, and interleukin-1 beta. Arterioscler Thromb Vasc Biol 16: 19-27, 1996.
105. Geng YJ, Henderson LE, Levesque EB, Muszynski M, Libby P: Fas is expressed in human atherosclerotic intima and promotes apoptosis of cytokine-primed human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 17: 2200-2208, 1997.
106. Mallat Z, Tedgui A: Apoptosis in the vasculature: mechanisms and functional importance. Br J Pharmacol 130: 947-962, 2000.
107. Wallner K, Li C, Shah PK, Wu KJ, Schwartz SM, Sharifi BG: EGF-like domain of tenascin-C is proapoptotic for cultured smooth muscle cells. Arterioscler Thromb Vasc Biol 24(8): 1416-1421, 2004.
108. Kolmakova A, Kwiterovich P, Virgil D, Alaupovic P, Knight-Gibson C, Martin SF, Chatterjee S: Apolipoprotein C-I induces apoptosis in human aortic smooth muscle cells via recruiting neutral sphingomyelinase. Arterioscler Thromb Vasc Biol 24(2): 264-269, 2004.
109. Durand E, Scoazec A, Lafont A, Boddaert J, Al Hajzen A, Addad F, Mirshahi M, Desnos M, Tedgui A, Mallat Z: In vivo induction of endothelial apoptosis leads to vessel thrombosis and endothelial denudation: a clue to the understanding of the mechanisms of thrombotic plaque erosion. Circulation 109(21): 2503-2506, 2004.
110. Sugiyama S, Kugiyama K, Aikawa M, Nakamura S, Ogawa H, Libby P: Hypochlorous acid, a macrophage product, induces endothelial apoptosis and tissue factor expression: involvement of myeloperoxidase-mediated oxidant in plaque erosion and thrombogenesis. Arterioscler Thromb Vasc Biol 24(7): 1309-1314, 2004.
111. Abela GS, Picon PD, Friedl SE, et al: Triggering of plaque disruption and arterial thrombosis in an atherosclerotic rabbit model. Circulation 91: 776-784, 1995.
112. Rekhter MD, Hicks GW, Brammer DW, et al: Animal model that mimics atherosclerotic plaque rupture. Circ Res 83: 705-713, 1998.
113. Caligiuri G, Levy B, Pernow J, Thoren P, Hansson GK: Myocardial infarction mediated by endothelin receptor signaling in hypercholesterolemic mice. Proc Natl Acad Sci USA 96: 6920-6924, 1999.
114. Rosenfeld ME, Polinsky P, Virmani R, Kauser K, Rubanyi G, Schwartz SM: Advanced atherosclerotic lesions in the innominate artery of the ApoE knockout mouse. Arterioscler Thromb Vasc Biol 20: 2587-2592, 2000.
115. Johnson JL, Jackson CL:. Atherosclerotic plaque rupture in the apolipoprotein E knockout mouse. Atherosclerosis 154: 399-406, 2001.
116. Lemaitre V, O'Byrne TK, Borczuk AC, Okada Y, Tall AR, D'Armiento J: ApoE knockout mice expressing human matrix metalloproteinase-1 in macrophages have less advanced atherosclerosis. J Clin Invest 107: 1227-1234, 2001.
117. Calara F, Silvestre M, Casanada F, Yuan N, Napoli C, Palinski W: Spontaneous plaque rupture and secondary thrombosis in apolipoprotein E-deficient and LDL receptor-deficient mice. J Pathol 195: 257-263, 2001.
118. von der Thusen JH, van Vlijmen BJ, Hoeben RC, Kockx MM, Havekes LM, van Berkel TJ, Biessen EA: Induction of atherosclerotic plaque rupture in apolipoprotein E-/-mice after adenovirus-mediated transfer of p53. Circulation 105: 2064-2070, 2002.
119. Muller JE, Tofler GH, Stone PH: Circadian variation and triggers of onset of acute cardiovascular disease. Circulation 79: 733-743, 1989.
120. Muller JE: Morning increase of onset of myocardial infarction. Implications concerning triggering events. Cardiology 76: 96-104, 1989.
121. Muller JE, Tofler GH: Triggering and hourly variation of onset of arterial thrombosis. Ann Epidemiol 2: 393-405, 1992.
122. Willich SN, Jimenez AH, Tofler GH, DeSilva RA, Muller JE: Pathophysiology and triggers of acute myocardial infarction: clinical implications. Clin Invest 70: S73-S78, 1992.
123. Willich SN, Maclure M, Mittleman M, Arntz HR, Muller JE: Sudden cardiac death. Support for a role of triggering in causation. Circulation 87: 1442-1450, 1993.
124. Peters A, Dockery DW, Muller JE, Mittleman MA: Increased particulate air pollution and the triggering of myocardial infarction. Circulation 103: 2810-2815, 2001.
125. Mittleman MA, Lewis RA, Maclure M, Sherwood JB, Muller JE: Triggering myocardial infarction by marijuana. Circulation 103: 2805-2809, 2001.
126. Muller JE: Circadian variation and triggering of acute coronary events. Am Heart J 137: S1-S8, 1999.
127. Muller JE: Triggering of cardiac events by sexual activity: findings from a case-crossover analysis. Am J Cardiol 86: 14F-18F, 2000.
128. Goldstein JA, Demetriou D, Grines CL, Pica M, Shoukfeh M, O'Neill WW: Multiple complex coronary plaques in patients with acute myocardial infarction. N Engl J Med 343: 915-922, 2000.
129. Matetzky S, Tani S, Kangavari S, et al: Smoking increases tissue factor expression in atherosclerotic plaques: implications for plaque thrombogenicity. Circulation 102: 602-604, 2000.
130. Burke AP, Kolodgie FD, Farb A, et al: Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation 103: 934-940, 2001.
131. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R: Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 336: 1276-1282, 1997.
132. Farb A, Burke AP, Tang AL, et al: Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation 93: 1354-1363, 1996.
133. Rauch U, Bonderman D, Bohrmann B, et al: Transfer of tissue factor from leukocytes to platelets is mediated by CD15 and tissue factor. Blood 96: 170-175, 2000.
134. Mallat Z, Benamer H, Hugel B, et al: Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 101: 841-843, 2000.
135. Laszik ZG, Zhou XJ, Ferrell GL, Silva FG, Esmon CT: Down-regulation of endothelial expression of endothelial cell protein C receptor and thrombomod-ulin in coronary atherosclerosis. Am J Pathol 159: 797-802, 2001.
136. Schwartz CJ, Valente AJ, Sprague EA, Kelley JL, Cayatte AJ, Mowery J: Atherosclerosis. Potential targets for stabilization and regression. Circulation 86: III117-III123, 1992.
137. Waters D: Plaque stabilization: a mechanism for the beneficial effect of lipid-lowering therapies in angiography studies. Prog Cardiovasc Dis 37: 107-120, 1994.
138. Shah PK: Pathophysiology of plaque rupture and the concept of plaque stabilization. Cardiol Clin 21: 303-314, 2003.
139. Shah PK: Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol 41: 15S-22S, 2003.
140. Kullo IJ, Edwards WD, Schwartz RS: Vulnerable plaque: pathobiology and clinical implications. Ann Intern Med 129: 1050-1060, 1998.
141. Lee RT: Plaque stabilization: the role of lipid lowering. Int J Cardiol 74 (Suppl 1): S11-S15, 2000.
142. Aikawa M, Rabkin E, Okada Y, et al: Lipid lowering by diet reduces matrix metalloproteinase activity and increases collagen content of rabbit atheroma: a potential mechanism of lesion stabilization. Circulation 97: 2433-2444, 1998.
143. Aikawa M, Libby P: Lipid lowering reduces proteolytic and prothrombotic potential in rabbit atheroma. Ann N Y Acad Sci 902: 140-152, 2000.
144. Aikawa M, Rabkin E, Sugiyama S, et al: An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metallopro-teinases and tissue factor in vivo and in vitro. Circulation 103: 276-283, 2001.
145. Fukumoto Y, Libby P, Rabkin E, et al: Statins alter smooth muscle cell accumulation and collagen content in established atheroma of Watanabe heritable hyperlipidemic rabbits. Circulation 103: 993-999, 2001.
146. Ameli S, Hultgardh-Nilsson A, Cercek B, et al: Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholes-terolemic rabbits. Circulation 90: 1935-1941, 1994.
147. Shah PK, Nilsson J, Kaul S, et al: Effects of recombinant apolipoprotein A-I [Milano] on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation 97: 780-785, 1998.
148. Shah PK, Yano J, Reyes O, et al: High-dose recombinant apolipoprotein A-I [Milano] mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice: potential implications for acute plaque stabilization. Circulation 103: 3047-3050, 2001.
149. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J: Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 103: 926-933, 2001.
150. Shah PK, Kaul S, Nilsson J, Cercek B: Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation 104: 2376-2383, 2001.
151. Shah PK, Kaul S, Nilsson J, Cercek B: Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part II. Circulation 104: 2498-2502, 2001.
152. Forrester J, Makkar R, Shah PK: Increasing HDL cholesterol in dyslipidemia by cholesterol ester transfer protein inhibition: an update for clinicians. Circulation 111: 1847-1854, 2005.
153. Li X, Chyu KY, Neto JR, Yano J, Nathwani N, Ferreira C, Dimayuga PC, Cercek B, Kaul S, Shah PK: Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation 110(12): 1701-1705, 2004.
154. Claudel T, Leibowitz MD, Fievet C, et al: Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc Natl Acad Sci USA 98: 2610-2615, 2001.
155. Kirkhamm TC, Williams CM: Endocannabinoid receptor antagonists: potential for obesity treatment. Treat Endocrinol 3(6): 345-360, 2004.